Stay up-to-date on our

Tempus AI Inc, collaboration agreement
September 15, 2025

Partnership with MVP Health Care
July 17, 2025

Growing collaboration with NYKHM
June 3, 2025

Medicare Issues Final Coverage Determination for kidneyintelX.dkd™
June 14, 2024

KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
March 14, 2024

New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease
January 10, 2024

Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd
August 3, 2023

Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions
July 7, 2023

FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease
June 29, 2023

Primary Care Use of KidneyIntelX in Early Stage CKD Improved Clinical Care Delivery and Outcomes
December 1, 2022

Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease
November 29, 2022

Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX™ with Primary Care Physicians
August 08, 2022

1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX™ Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients
June 10, 2022

KidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort
June 6, 2022

Renalytix Announces Two Data Presentations on KidneyIntelX™ at American Diabetes Association 82nd Scientific Sessions^®
June 2, 2022